Filed pursuant to Rule 424(b)(3)
Registration Statement No. 333-262339
Prospectus Supplement No. 15
(To Prospectus
dated March 21, 2022)
eFFECTOR Therapeutics, Inc.
This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the Prospectus), which forms a part of our
Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in this prospectus supplement and not otherwise defined
herein have the meanings specified in the Prospectus.
This prospectus supplement is being filed to update, amend and supplement the information included
in the Prospectus with the information contained in our Current Report on Form 8-K (the Current Report), filed with the SEC on February 21, 2023. Accordingly, we have attached the
Current Report to this prospectus supplement.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be
read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information
contained in the Prospectus.
Our common stock and warrants are listed on the Nasdaq Capital Market under the symbols EFTR and
EFTRW. On February 17, 2023, the closing price of our common stock was $0.61 and the closing price of our warrants was $0.17.
We are
an emerging growth company under federal securities laws and are subject to reduced public company reporting requirements. Investing in our securities involves certain risks. See Risk Factors beginning on page 7 of the
Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of
this prospectus supplement is February 21, 2023.